Claims for Patent: 8,486,403

Summary for Patent: 8,486,403

Title:	Method of promoting bone growth by an anti-activin A antibody
Abstract:	In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Inventor(s):	Knopf; John (Carlisle, MA), Seehra; Jasbir (Lexington, MA)
Assignee:	Acceleron Pharma, Inc. (Cambridge, MA)
Application Number:	13/357,264
Patent Claims:	1. A method for promoting bone growth, increasing bone density, or increasing bone strength, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody. 2. The method of claim 1, wherein the anti-activin A antibody is a monoclonal antibody. 3. The method of claim 1, wherein the method is for promoting bone growth in a subject in need thereof. 4. The method of claim 1, wherein the method is for increasing bone density in a subject in need thereof. 5. The method of claim 1, wherein the method is for increasing bone strength in a subject in need thereof. 6. The method of claim 1, wherein the method further comprises administering a second bone-active agent. 7. The method of claim 6, wherein the bone-active agent is selected from a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 8. The method of claim 1, wherein the anti-activin A antibody is a humanized or fully human antibody. 9. A method for treating a bone-related disorder, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody, wherein the bone-related disorder is associated with low bone density or decreased bone strength. 10. The method of claim 9, wherein the bone-related disorder is primary osteoporosis. 11. The method of claim 9, wherein the bone-related disorder is post-menopausal osteoporosis. 12. The method of claim 9 wherein the method further comprises administering a second bone-active agent. 13. The method of claim 12, wherein the bone-active agent is selected from the group consisting of: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 14. The method of claim 9, wherein the bone-related disorder is secondary osteoporosis. 15. The method of claim 9, wherein the bone-related disorder is hypogonadal bone loss. 16. The method of claim 9, wherein the subject has a cancer that is associated with bone loss. 17. The method of claim 9, wherein the subject is the recipient of a cancer treatment regimen than is associated with bone loss. 18. The method of claim 9, wherein the bone-related disorder is bone metastases. 19. The method of claim 9, wherein the bone-related disorder is multiple myeloma. 20. The method of claim 9, wherein the bone-related disorder is Paget's disease. 21. The method of claim 9, wherein the subject has a cancer that is associated with bone metastases. 22. The method of claim 21, wherein the subject is positive for an indicator of loss of bone density, bone resorption, or bone metastases. 23. The method of claim 9, wherein the anti-activin A antibody is a monoclonal antibody. 24. The method of claim 9, wherein the anti-activin A antibody is a humanized or fully human antibody. 25. A method for promoting bone growth and inhibiting bone resorption in a patient, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody. 26. The method of claim 25, wherein the method causes less than a 10% increase in the patient's skeletal muscle mass. 27. The method of claim 25, wherein the method further comprises administering a second bone-active agent. 28. The method of claim 27, wherein the bone-active agent is selected from a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 29. The method of claim 25, wherein the anti-activin A antibody is a monoclonal antibody. 30. The method of claim 25, wherein the anti-activin A antibody is a humanized or fully human antibody.

Details for Patent 8,486,403

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2025-11-23